NRX PHARMACEUTICALS INC

NRX Pharmaceuticals: A clinical‑stage firm battling market volatility while pushing Covid‑19, respiratory, depression, and PTSD therapies.

NRX Pharmaceuticals Inc. (NRXP) is a clinical‑stage biotech pushing treatments for COVID‑19, respiratory disease, suicidal depression and PTSD, trading below earnings and book value with a $76 million market cap; investors watch its breakthrough pot…

NRX Pharmaceuticals’ stock slump, negative P/E and low market cap reflect investor doubts, yet the firm pushes forward with Covid‑19, depression, PTSD, and respiratory drug development.

NRX Pharmaceuticals becomes debt‑free by converting $5.4 million debt into equity, boosting growth prospects for its Covid‑19 and mental‑health drugs.

NRX Pharmaceuticals’ 3.5% pre‑market rally shows how biotech gains and positive peer sentiment can lift early‑stage stocks, hinting at future upside if clinical milestones and funding materialize.

NRX Pharmaceuticals, a clinical-stage pharmaceutical company, is navigating the challenges of the biotech sector with a focus on developing investigational medicines for critical areas such as Covid-19, respiratory conditions, suicidal depression, a…

NRX Pharmaceuticals continues to advance in clinical research, focusing on treatments for Covid-19, respiratory conditions, suicidal depression, and PTSD.

NRX Pharmaceuticals Inc. has gained significant attention after receiving FDA Fast Track designation for its investigational drug NRX-100, which aims to treat suicidal ideation in patients with depression.